Amryt signs distribution agreement in Switzerland
Irish-listed Amryt Pharma, which is focused on finding treatments for rare and orphan diseases, has signed a distribution agreement for the company’s Lojuxta (lomitapide) product in Switzerland.
The agreement is with RCC Pharma, a Swiss pharmaceutical company with expertise in early access programs in rare and orphan diseases.
Lojuxta is a treatment for Homozygous Familial Hypercholesterolaemia ("HoFH"), a rare, life-limiting disease, which impairs the body's ability to remove bad cholesterol from the blood.
The disease process starts before birth and progresses rapidly and typically results in extremely high bad cholesterol levels in blood, leading to aggressive and premature narrowing and blocking of blood vessels.
Left untreated, heart attack or sudden death may occur in childhood or early adulthood.
Amryt estimates that there are currently approximately 15 patients with HoFH in Switzerland.
"This new distribution agreement with RCC marks another key step as we expand our footprint for Lojuxta across Europe, the Middle East, and North Africa," Dr. Joe Wiley, CEO of Amryt, said.
"We continue to work on further partnerships across our licensed territories for Lojuxta, and look forward to announcing further developments."
The new agreement follows a distribution agreement, announced in November, which covers Amryt's products for Saudi Arabia.
Amryt acquired exclusive marketing rights for Lojuxta in the European Economic Area, Switzerland, Middle East, North Africa, Turkey and Israel in December 2016.